Tricyclic SOS1 Inhibitors for RAS Pathway Attenuation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for SOS1 inhibitory compounds to treat diseases or disorders, particularly cancer, that are dependent on SOS1, as existing treatments are inadequate in modulating the RAS-mediated signaling pathways effectively.
Innovation Solution
Development of substituted tricyclic compounds represented by general formula (I) and their pharmaceutically acceptable salts, which act as potent inhibitors of SOS1, targeting various diseases or disorders by inhibiting SOS1 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used to modulate RAS-mediated signaling pathways, then treatment options are limited, but therapeutic efficacy is insufficient
Solution Approach 1:
The patent segments the RAS signaling pathway into distinct targetable components, specifically identifying SOS1 as a separable target from RAS itself. By developing SOS1 inhibitors that act upstream of RAS, the treatment approach is segmented into pathway-specific interventions, providing new therapeutic options while maintaining efficacy against RAS-driven cancers.
Solution Approach 2:
The patent introduces SOS1 inhibitors as intermediary compounds that mediate the inhibition of RAS activity indirectly. Rather than targeting RAS directly, these compounds bind to SOS1 (a guanine nucleotide exchange factor) and prevent it from activating RAS, creating an intermediary layer of inhibition that overcomes the limitations of existing direct RAS targeting approaches.
2Reliability
If SOS1 is targeted to inhibit RAS-mediated pathways, then downstream effector events are attenuated, but drug development challenges remain
Solution Approach 1:
The patent performs preliminary identification and characterization of SOS1 as a drug-targetable entity before full-scale drug development. By establishing SOS1's role as a critical upstream regulator of RAS and demonstrating its druggability through binding assays and structural analysis, the patent prepares the groundwork for subsequent drug development, reducing later-stage risks and improving feasibility.
Solution Approach 2:
The patent employs parameter changes in the design of SOS1 inhibitor compounds, optimizing molecular properties such as binding affinity, selectivity, and pharmacokinetic parameters. By systematically varying chemical structures and measuring their effects on SOS1 inhibition, the patent identifies optimal compounds that balance efficacy with developability, addressing manufacturing and clinical translation challenges.
Data Source
AI summary
Disclosed are compounds of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, or solvate thereof, wherein, ring A, ring B, R1 to R4, and n are as defined herein, for use as SOS1 inhibitors in the treatment of proliferative, infectious and RASopathy diseases or disorders. Also disclosed are methods of synthesizing the compound of formula I, pharmaceutical compositions containing the compound of formula I, method of treatment of proliferative, infectious and RASopathy diseases or disorder, for example, a cancer, by administering the said compound and combinations of the compound of formula I with other active ingredients.